References
- Philandrianos C, Kerfant N, Jaloux C, Jr, et al. [Keloid scars (part I): clinical presentation, epidemiology, histology and pathogenesis]. Annales de Chirurgie Plastique et Esthetique. 2016;61(2):128–135. French.
- Ogawa R, Akaishi S. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - keloids and hypertrophic scars may be vascular disorders. Med Hypotheses. 2016;96:51–60.
- Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci. 2017;18(3):606.
- Ridiandries A, Bursill C, Tan J. Broad-spectrum inhibition of the CC-chemokine class improves wound healing and wound angiogenesis. Int J Mol Sci. 2017;18(1):155.
- Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: mining tens of millions of expression profiles–database and tools update. Nucleic Acids Res. 2007;35:D760–D765.
- Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–210.
- Matsumoto NM, Aoki M, Okubo Y, et al. Gene expression profile of isolated dermal vascular endothelial cells in keloids. Front Cell Dev Biol. 2020;8:658.
- Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25(1):25–29.
- Kanehisa M, Goto S, Furumichi M, et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010;38:D355–D360.
- Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447–D452.
- Smoot ME, Ono K, Ruscheinski J, et al. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27(3):431–432.
- Bandettini WP, Kellman P, Mancini C, et al. MultiContrast delayed enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 2012;14(1):83.
- Huang C, Akaishi S, Hyakusoku H, et al. Are keloid and hypertrophic scar different forms of the same disorder? A fibroproliferative skin disorder hypothesis based on keloid findings. Int Wound J. 2014;11(5):517–522.
- Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg. 2017;43(1):S3–S18.
- Ma X, Chen J, Xu B, et al. Keloid-derived keratinocytes acquire a fibroblast-like appearance and an enhanced invasive capacity in a hypoxic microenvironment in vitro. Int J Mol Med. 2015;35(5):1246–1256.
- Clouthier DL, Harris CN, Harris RA, et al. Requisite role for Nck adaptors in cardiovascular development, endothelial-to-mesenchymal transition, and directed cell migration. Mol Cell Biol. 2015;35(9):1573–1587.
- Lee SY, Kim EK, Seo HB, et al. IL-17 induced stromal cell-derived factor-1 and profibrotic factor in keloid-derived skin fibroblasts via the STAT3 pathway. Inflammation. 2020;43(2):664–672.
- Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610–621.
- Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – a target for novel cancer therapy. Cancer Treatment Rev. 2018;63:40–47.
- Ding Q, Lu P, Xia Y, et al. CXCL9: evidence and contradictions for its role in tumor progression. Cancer Med. 2016;5(11):3246–3259.
- Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.
- Pozzobon T, Goldoni G, Viola A, et al. CXCR4 signaling in health and disease. Immunol Lett. 2016;177:6–15.
- Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018;285(16):2944–2971.
- Kuida K. Caspase-9. Int J Biochem Cell Biol. 2000;32(2):121–124.
- Zhang MZ, Dong XH, Guan EL, et al. A comparison of apoptosis levels in keloid tissue, physiological scars and normal skin. Am J Transl Res. 2017;9(12):5548–5557.